$181.7M deal: Strongbridge to sell rights to hormone drug to Novo Nordisk

Strongbridge Biopharma entered into an agreement to sell the U.S. and Canadian rights to its adult growth hormone deficiency drug Macrilen to Novo Nordisk for an upfront payment of $145 million, plus an equity investment of $36.7 million. The deal, expected to close next month, also includes Nova Nordisk of Denmark paying the company undisclosed royalties on the sales of Macrilen through 2027 and using and funding Strongbridge’s rare endocrine commercial field organization for Macrilen for up…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news